Estimands and Doubly Robust Estimation for Cluster-Randomized Trials With Survival Outcomes. [PDF]
Fang X, Wang B, Hu L, Li F.
europepmc +1 more source
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket +14 more
wiley +1 more source
SPARCC: Semi-Parametric Robust Estimation in a Right-Censored Covariate Model. [PDF]
Lee SH +4 more
europepmc +1 more source
ABSTRACT Background Collaterals are crucial factors that influence the infarct growth rate (IGR). We aimed to determine whether a comprehensive multimodal collateral score (MCS), incorporating collateral assessment at the arterial, tissue, and venous levels, is associated with functional independence and provides incremental prognostic value over ...
Giorgio Busto +12 more
wiley +1 more source
Doubly Robust Estimation and Sensitivity Analysis With Outcomes Truncated by Death in Multi-Arm Clinical Trials. [PDF]
Tong J +4 more
europepmc +1 more source
Robust estimation of cortical similarity networks from brain MRI. [PDF]
Sebenius I +8 more
europepmc +1 more source
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi +9 more
wiley +1 more source
Handling incomplete outcomes and covariates in cluster-randomized trials: doubly robust estimation, efficiency considerations, and sensitivity analysis. [PDF]
Wang B, Li F, Wang R.
europepmc +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
Censoring-robust estimation in fixed sample time-to-event clinical trials with adaptive randomization. [PDF]
Hakhu NR, Gillen DL.
europepmc +1 more source

